Potent protein phosphotyrosine phosphatase inhibitor Insulin receptor kinase (IRK) inducer. Insulin mimetic in vitro and in vivo. Apoptosis inducer. ERK inducer. Mitogen-activated protein kinase phosphatase-1 (MKP-1) inducer. Angiogenesis inhibitor.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
K . 3H2O
Purity: >99% (51V-NMR)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics: B.I. Posner, et al.; J. Biol. Chem. 269, 4596 (1994)
Early signaling events triggered by peroxovanadium are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen): C.J. Band, et al.; Mol. Endocrinol. 11, 1899 (1997)
Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats: J.F. Yale, et al.; Diabetes 44, 1274 (1995)
In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency: A.P. Bevan, et al.; Am. J. Physiol. 268, E60 (1995)
A role for tyrosine phosphorylation in both activation and inhibition of the insulin receptor tyrosine kinase in vivo: P.G. Drake, et al.; Endocrinology 137, 4960 (1996)
BpV (phen) induces apoptosis of RINm5F cells by modulation of MAPKs and MKP-1: L. Rumora, et al.; BBRC 300, 877 (2003)
Positive regulation of ERK activation and MKP-1 expression by peroxovanadium complex bpV (phen): L. Rumora, et al.; Cell Biol. Toxicol. 20, 293 (2004)
Peroxovanadium compounds as inhibitors of angiogenesis: C. J. Doillon, et al.; Angiogenesis 3, 361 (1999)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|